2-Methylimidazo[1,2-a]pyridine-7-carbonitrile | 952511-42-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 2-Methylimidazo[1,2-a]pyridine-7-carbonitrile
• CAS: 952511-42-1
• 化学式: C₉H₇N₃
• 分子量: 157.175
• InChiKey: XOEVDPHIYOLYBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] RHO KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA RHO KINASE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012006202A1

  公开（公告）日：2012-01-12

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of Rho Kinase-mediated disorders selected from hypertension, atherosclerosis, restenosis, stroke, myocardial infarction, heart failure, coronary artery disease, peripheral artery disease, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, erectile dysfunction, renal disease, organ failure, asthma, glaucoma, cancer, Alzheimer's disease, multiple sclerosis, spinal cord injury, neuropathic pain, rheumatoid arthritis, psoriasis inflammatory bowel disease, and combinations of such disorders.

  本发明涉及化合物的结构式（I）及其药学上可接受的盐，其中R1和X如本文所定义。本发明还涉及包含这些化合物的制药组合物，以及使用这些化合物治疗从高血压、动脉粥样硬化、再狭窄、中风、心肌梗死、心力衰竭、冠状动脉疾病、外周动脉疾病、冠状动脉痉挛、脑血管痉挛、缺血/再灌注损伤、肺动脉高压、心绞痛、勃起功能障碍、肾脏疾病、器官衰竭、哮喘、青光眼、癌症、阿尔茨海默病、多发性硬化症、脊髓损伤、神经性疼痛、类风湿性关节炎、银屑病、炎症性肠病等Rho激酶介导的疾病的方法，以及这些疾病的组合。
• HETERO COMPOUND
  申请人：HARADA Hironori

  公开号：US20090076070A1

  公开（公告）日：2009-03-19

  [Problems] To provide a useful compound as an active ingredient for a preventing and/or treating agent for rejection in the transplantation of an organ, bone marrow, or a tissue, an autoimmune disease, or the like, which has an excellent S1P 1 agonist activity. [Means for Solving] Since the compound of the invention has an S1P 1 agonist activity, it is useful as an active ingredient for a treating or preventing agent for a disease caused by unfavorable lymphocytic infiltration, for example, an autoimmune disease such as graft rejection in the transplantation of an organ, bone marrow, or a tissue, a graft-versus-host disease, rheumatic arthritis, multiple sclerosis, systemic lupus erythematosus, a nephrotic syndrome, encephalomeningitis, myasthenia gravis, pancreatitis, hepatitis, nephritis, diabetes, pulmonary disorder, asthma, atopic dermatitis, inflammatory bowel disease, atherosclerosis, ischemia-reperfusion injury, or an inflammatory disease, and further, a disease caused by the abnormal growth or accumulation of cells such as cancer and leukemia.

  [问题] 提供一种有优异S1P1激动剂活性的化合物，作为器官、骨髓或组织移植、自身免疫性疾病等引起的排异的预防和/或治疗剂的有效活性成分。 [解决方法] 由于本发明的化合物具有S1P1激动剂活性，因此可用作治疗或预防由不良淋巴细胞浸润引起的疾病的活性成分，例如器官、骨髓或组织移植的移植排斥、移植物抗宿主病、风湿性关节炎、多发性硬化症、全身性红斑狼疮、肾病综合症、脑脊髓炎、重症肌无力、胰腺炎、肝炎、肾炎、糖尿病、肺部疾病、哮喘、特应性皮炎、炎症性肠病、动脉粥样硬化、缺血再灌注损伤或异常细胞生长或积累引起的癌症和白血病等疾病。
• RHO KINASE INHIBITORS
  申请人：Cook Brian Nicholas

  公开号：US20120165322A1

  公开（公告）日：2012-06-28

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物和其药学上可接受的盐，其中R1和R2的定义如本文所述。本发明还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和障碍的方法、制备这些化合物的过程以及在这些过程中有用的中间体。
• PHENOXYMETHYL HETEROCYCLIC COMPOUNDS
  申请人：ENVIVO PHAMACEUTICALS, INC.

  公开号：US20130143888A1

  公开（公告）日：2013-06-06

  Phenoxymethyl compounds that inhibit at least one phosphodiesterase 10 are described as are pharmaceutical compositions containing such compounds an methods for treating various CNS disorders by administering such compounds to a patient in need thereof.

  本文描述了抑制至少一种磷酸二酯酶10的苯甲氧基化合物，以及包含这些化合物的药物组合物和通过将这些化合物用于需要治疗的患者来治疗各种中枢神经系统疾病的方法。
• N-CYCLYL-3-(CYCLYLCARBONYLAMINOMETHYL)BENZAMIDE DERIVATIVES AS RHO KINASE INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2590950B1

  公开（公告）日：2014-10-15